1. What's New in Therapeutic Options for Moderate to Severe RA?

3. Introduction/Overview

4. Taxonomy of Inadequate Responders to RA Therapeutics

5. Different RA Combination Treatments Centered on MTX

6. EULAR Recommendations: 2016

7. Earlier Identification of the Individual at Risk for RA

8. Identification of Patients at Risk for Rapid RA Progression

9. Approaches for the Non-Responding Patient With RA

10. Many Cytokines and Growth Factors Converge on JAK Signaling Pathways

11. The Biological Significance of Signaling Through Different JAK Combinations

12. Baricitinib (JAK 1/2 Inhibitor): Key Studies in RA Phase 3 Program and Their Characteristics

13. RA-BEACON: Study Design

14. RA-BEACON: Baricitinib in Patients With RA and an Inadequate Response to TNF-a Inhibitors

15. Potential Benefits of the JAK 1/2 Inhibitor Baricitinib

17. Tofacitinib (JAK1/3 Inhibitor): Key Studies in RA Phase 3 Program and Their Characteristics

18. ORAL Scan: Change in Radiographic Progression, Tofacitinib (5 mg, 10 mg) vs Placebo

19. Tofacitinib or ADA vs PBO in RA: Results From ORAL Standard

20. Comparing Clinical Results of JAK1/3 and JAK1/2 Inhibitors

21. DARWIN 1 Phase 2: ACR Outcomes at Week 12 in MTX-IR: Filgotinib + MTX in Patients With Active RA

22. Other JAK Inhibitors in Development: Upadacitinib

23. JAK Inhibitors: Safety Considerations

24. Types of Therapies for RA

25. EULAR Recommendations 2016: What to Do After MTX Failure

26. Appropriate Management of RA

27. Summary and Conclusions

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)

31. Abbreviations (cont)